ARTICLE | Company News
Agouron other research news
March 27, 1995 8:00 AM UTC
At the meeting of the American Association of Cancer Research in Toronto, AGPH (La Jolla, Calif.) reported Phase I results showing anti-tumor effects of AG337 in several patients.
A study with escalating doses given as a five-day infusion every three weeks found the maximum tolerated dose in the 19 patients to be 1130 mg/m2. Dose-limiting toxicity was myelosuppression and mucositis, both of limited duration. ...